Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement - Breast Cancer Survivorship

McMaster University

$100,000.00

Simultaneous Integrated Boost (SIB) for Ultra-Hypofractionated (UH) Adjuvant Radiotherapy in High Risk Early Stage Breast Cancer

EF 2025-26

Résumé
After breast conserving surgery (BCS) patients with breast cancer receive whole breast irradiation (WBI) to reduce the risk of local recurrence (LR) of cancer. This is now usually given in 5 daily treatments over 1 week. There are some patients with cancers that are at increased risk of recurrence who are treated with additional radiotherapy (RT) called "boost" to the surgical bed. The boost is given in 5 additional daily treatments over 1 week sequentially after WBI of 1 week. Boost treatment could potentially be given at the same time as WBI using advances in radiation technology to give a slightly higher dose to the surgical bed on each of the 5 days of RT called "simultaneous integrated boost" (SIB). This would shorten treatment by a week and allow for fewer side effects, improved patient convenience, and reduced costs to patients and the health care system. The objective of this study is to determine if SIB compared to sequential boost RT results in non-inferior rates of LR. Secondary outcomes will include: toxicity, adverse cosmesis, quality of life, disease-free, and overall survival. A multicentre randomized trial will be performed. Patients will be randomized to SIB with WBI (5 treatments over 1 week) or WBI followed by the sequential boost (10 treatments over 2 weeks). Eligible patients will be those with ductal carcinoma in situ, node negative or positive breast cancer with high risk features (age <50 years, large size, grade 3 disease, or close margins of excision). Patients will be followed yearly for recurrence and toxicity. Cosmetic appearance will be self-assessed by patients at baseline, and 3 years following randomization. The planned sample size is 1646 patients (823 per arm) to determine if LR with SIB is not inferior to that with sequential boost. If we are able to show that SIB is not inferior to the sequential boost, patients will have access to a treatment which has less toxicity, is more convenient and less costly.
Programme
Project Grant - Priority Announcement - Breast Cancer Survivorship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
553258
Name
Donovan Elysia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Randomized Controlled Trials 3
Projecttitle
Simultaneous Integrated Boost (SIB) for Ultra-Hypofractionated (UH) Adjuvant Radiotherapy in High Risk Early Stage Breast Cancer
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement - Breast Cancer Survivorship
Keyworddelim
Breast Cancer; Breast Conserving Therapy; Radiotherapy; Sequential Boost; Simultaneous Integrated Boost; Ultra-Hypofractionation
Abstract
After breast conserving surgery (BCS) patients with breast cancer receive whole breast irradiation (WBI) to reduce the risk of local recurrence (LR) of cancer. This is now usually given in 5 daily treatments over 1 week. There are some patients with cancers that are at increased risk of recurrence who are treated with additional radiotherapy (RT) called "boost" to the surgical bed. The boost is given in 5 additional daily treatments over 1 week sequentially after WBI of 1 week. Boost treatment could potentially be given at the same time as WBI using advances in radiation technology to give a slightly higher dose to the surgical bed on each of the 5 days of RT called "simultaneous integrated boost" (SIB). This would shorten treatment by a week and allow for fewer side effects, improved patient convenience, and reduced costs to patients and the health care system. The objective of this study is to determine if SIB compared to sequential boost RT results in non-inferior rates of LR. Secondary outcomes will include: toxicity, adverse cosmesis, quality of life, disease-free, and overall survival. A multicentre randomized trial will be performed. Patients will be randomized to SIB with WBI (5 treatments over 1 week) or WBI followed by the sequential boost (10 treatments over 2 weeks). Eligible patients will be those with ductal carcinoma in situ, node negative or positive breast cancer with high risk features (age <50 years, large size, grade 3 disease, or close margins of excision). Patients will be followed yearly for recurrence and toxicity. Cosmetic appearance will be self-assessed by patients at baseline, and 3 years following randomization. The planned sample size is 1646 patients (823 per arm) to determine if LR with SIB is not inferior to that with sequential boost. If we are able to show that SIB is not inferior to the sequential boost, patients will have access to a treatment which has less toxicity, is more convenient and less costly.
Competitiondate
202509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Donovan, Elysia; Parpia, Sameer; Whelan, Timothy J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~